earuphoria.
All podcasts
Medicine · News · Science

Mendelspod Podcast

Theral Timpson
Rights holder? Report thismendelspod.com

Episodes

November 19, 2026

When to Begin Developing the Companion Diagnostic? With Gulzar Sandhu, Agilent Technologies

When should a pharma company begin developing the diagnostic that will identify which patients benefit from a new drug? Early enough to avoid costly delays, but not so early that the company limits the possibilities for the drug. Gulzar Sandhu, Head of Business Development for Biopharma Assay Development at Agilent Technologies, joins us to explore this delicate balance. Companion diagnostics can dramatically improve clinical trial outcomes by identifying patients most likely to respond to a therapy. But developing these tests requires significant investment. Still, to delay can be costly and endanger the entire drug program. ...

November 12, 2026

The $60 Genome, Virtual Cell Modeling and the Future of Biology, with Gilad Almogy, Ultima Genomics

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com Can we scale our way to a better understanding of biology? When we first had the CEO and founder of Ultima Genomics on the show, the company had just emerged from stealth with an ambitious vision. Coming from the semiconductor industry, Gilad Almogy believed that dramatically reducing the cost of DNA sequencing would enable scientists to study biology at an entirely new scale. And that scale would lead to discoveries we couldn’t yet imagine. A few years later, Ul...

November 5, 2026

Precision Oncology 2.0: From Tumor Profiling to Continuous Monitoring with Jerry Radich, Fred Hutch

Precision oncology is entering a new phase. Rather than simply profiling a tumor and matching it to a drug, physicians are increasingly able to follow a patient’s cancer over time, measuring treatment response, detecting residual disease, and adjusting therapy as the disease evolves. Jerry Radich of Fred Hutch Cancer Center has been at the forefront of this evolution. His pioneering work in chronic myeloid leukemia (CML) helped establish molecular monitoring as a critical part of cancer care and prefigured the rise we see in MRD testing today. Some CML patients can even discontinue treatment after achieving a...

November 3, 2026

The UK’s Next Big Bet on Precision Medicine: Our Future Health with CEO Raghib Ali

In the US, we have the All of Us Research Program. In the UK, they have Our Future Health, an ambitious new population health research program that aims to make healthcare more preventive than reactive. Launched just four years ago, it has already recruited nearly three million volunteers toward a goal of five million, making it one of the world’s largest health research initiatives. Today we’re joined by Raghib Ali, CEO and Principal Investigator of Our Future Health, to discuss how the program builds on the success of UK Biobank while pursuing a different goal. Rath...

October 27, 2026

From the Archives: The Dark Genome Is Coming Into Focus with Sudhakaran Prabakaran

In recent months on Mendelspod, we’ve explored how new sequencing and proteomics technologies are revealing biology in regions of the genome (and proteome) that have long escaped our attention. From repeat expansion disorders to new approaches in cancer diagnostics, the dark genome is increasingly becoming clinically relevant. Today we’re revisiting a conversation from earlier in the year that asks an even bigger question. What if much of this unexplored genomic territory is not simply functional, but a reservoir of evolutionary possibility? Last March, we talked with Sudhakaran Prabakaran, computational biologist at Northeastern University, foun...

October 19, 2026

Repeat Expansions and the Promise of Long Reads with Alex Lindell and Simon Sadedin

Repeat expansions are places where the genome has remained stubbornly dark. Long-read sequencing is beginning to illuminate them, and now that new visibility is moving into clinical testing. Today we’re joined by Simon Sadedin, Head of Clinical Bioinformatics at Victorian Clinical Genetics Services in Australia, and Alex Lindell, Senior Director of Product Marketing at Oxford Nanopore. Until now, testing for repeat expansions has largely meant building a separate assay for each disorder. A patient might be tested for Fragile X, get a negative result, and then move on to another test, sometimes waiting months at...

October 15, 2026

How Roswell Park Is Rethinking Molecular Testing for Blood Cancers with Sean Glenn

Sometimes the best evidence that a new medical technology is working is simply that doctors start depending on it. For years, the promise of molecular medicine has been that better genomic information would lead to better patient care. At Roswell Park Comprehensive Cancer Center, Vice Chair of Molecular Pathology, Sean Glenn, offers a compelling example of that promise becoming routine clinical practice. Hematologic cancers can require information from many different kinds of genomic alterations and traditionally from multiple tests and laboratories. Glenn and his team developed a comprehensive pan-hematological assay that brings much of that information together...

October 14, 2026

Building a Single Cell Atlas of the Poplar Tree with Robin Buell and Anita Giabardo

Plant biology too is benefiting from single cell resolution. Unlike animals, plants cannot move away from environmental stress. They have evolved tremendous biological complexity to stay rooted in one place. Their genomes are complex too, with repeated genome duplications producing families of related genes that can take on different functions. And within a single leaf are many specialized cell types, from photosynthetic and epidermal cells to vasculature and rare trichomes, each with its own patterns of gene expression. It’s early days for plant science. The field is only beginning to assemble the large, high qu...

October 13, 2026

Three Illumina 5-Base Grant Contest Winners Share Cancer Research Insights from Combining Epigenetics and Genetics

What new insights can we learn about cancer when researchers are able to look at the genome and the methylome together? Recently, Illumina launched its 5-base for Cancer Research Grant Contest to explore that question. Today, the three winners join us on Mendelspod with three very different problems in cancer research. Richard Tothill of the University of Melbourne is studying cancers of unknown primary and in collaboration with Hartwig Medical Foundation is combining DNA methylation and mutation profiling to reveal the primary origins of these aggressive cancers. Jacob Blum of Johns Hopkins is working with...

October 8, 2026

Ten Years Ago Mike Joyner Was Skeptical of Precision Medicine. What Does He Say Today?

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com A recent New York Times article highlighted a remarkable study showing that exercise can help keep colon cancer in remission. After eight years, 90 percent of patients in a structured exercise program were still alive, compared with 83 percent in the control group. Yet despite these results, such programs are rarely covered by insurance. It’s a striking example of something our guest today, Mayo Clinic physiologist Mike Joyner, has argued for years. Are we overlooking some of the most powerful ways to im...

September 29, 2026

Deeper into the Genome: Google DeepMind’s Ziga Avsec on the New AlphaGenome Atlas

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com Is biology headed back into the genome? While much of biology has been expanding outward into single cells, spatial biology and ever more biological context, Žiga Avsec and his team at Google DeepMind are making the case that there is still an enormous amount to learn by going deeper into DNA itself. Their new AlphaGenome Atlas uses AlphaGenome to predict the molecular effects of every possible single letter change in the human genome. That’s some nine bil...

September 22, 2026

Mass Spec Comes to the Routine Core Lab: Don Mason of Roche on a New Era in Clinical Testing

Mass spectrometry has been one of the most powerful technologies in clinical testing for decades. So why is it still largely confined to specialty labs? Don Mason has spent more than 25 years in clinical mass spectrometry. Now Senior Marketing Manager for Mass Spectrometry at Roche Diagnostics, he says the technology’s strength has also been its weakness: “Part of its power and part of its challenges are linked.” Mass spec is extraordinarily sensitive, selective and flexible, but traditionally requires specialized operators, complicated workflows and batch processing. That may finally be changing. Last year Roche launched their...

September 17, 2026

Jennifer Dionne Wants to Read the Whole Proteome Using Nanophotonics, i.e. Raman Spectroscopy

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com Jennifer Dionne, Stanford physicist and co-founder of Pumpkinseed, joins us to talk about a radically different way of reading proteins. Pumpkinseed’s deSIPHR technology combines nanophotonics with Raman spectroscopy to detect the molecular vibrations of individual amino acids. The goal is de novo protein sequencing that can read not only the 20 canonical amino acids, but potentially the enormous alphabet created by post-translational modifications and other forms of protein variation. Raman spectroscopy is super cool even if nearly a century ol...

September 15, 2026

Katie Maloney, Partner at DeciBio Consulting, Sees an Inflection Point for Digital and Computational Pathology

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com Digital technology has been promising to transform pathology for years. But the last year looks different. Roche paid roughly $1 billion for PathAI. Tempus acquired Paige. Other deals are adding to a sudden wave of consolidation. And AstraZeneca is developing a computational pathology algorithm for TROP2 that could become a companion diagnostic used to determine which patients receive a drug. DeciBio partner Katie Maloney says these are signs that digital pathology may finally be reaching an inflection point. ...

September 11, 2026

It’s One of the Greatest Success Stories of Molecular Medicine. Genomics Historian Kevin Davies on His Latest Book about Casgevy and Sickle Cell Disease

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com It was the heady days of the CRISPR revolution and of the gene therapy Casgevy. And when longtime genomics editor and author Kevin Davies went looking for a book that told the story of sickle cell disease and could not find one, he was perplexed and then inspired. A few years later, the result is Curved Air, a biography of sickle cell anemia that traces one of the most remarkable arcs in modern biology. Davies begins with Victoria Gray...

September 10, 2026

Elias Sayour on the Cancer Vaccine Breakthrough

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com After being pursued for more than 150 years, cancer vaccines may finally be having their moment. The recent positive Phase III results from Moderna and Merck offer what today’s guest Dr. Elias Sayour calls the first “bona fide evidence” that a therapeutic personalized cancer vaccine can work. For Sayour, a pediatric oncologist and cancer researcher at the University of Florida, the result is not the culmination of the field. It is “just the tip of the iceberg.” Sayour exp...

September 8, 2026

What Single Cell Sequencing Revealed About Pulmonary Fibrosis with Nick Banovich, TGen

Single cell sequencing has given researchers extraordinary new maps of human biology. For Nick Banovich of TGen, the burning question is how to turn those maps into something that matters for patients. Banovich has spent much of his career studying pulmonary fibrosis, and single cell sequencing has changed the field’s understanding of the disease. Instead of looking at an average signal from diseased lung tissue, researchers can now separate molecular changes from changes in the populations of cells themselves. That has helped point drug developers away from simply targeting fibrosis and toward earlier changes in epithelial an...

September 3, 2026

The Quest to Measure Protein Function with Polly Fordyce, Stanford

Stanford physicist and bioengineer Polly Fordyce has a big vision. She’s attempting to measure protein function at the scale at which we learned to measure DNA. We can sequence proteins. We can increasingly predict their structures. But we still have a surprisingly difficult time measuring what proteins actually do. Fordyce wants to change that. Her lab is developing ways to measure protein folding, binding, kinetics and function at a massive scale, using the quantitative language of physics. Her ambition is not simply to create more protein data. She wants measurements good enough to make biology more pr...

September 1, 2026

Doubling Down on Long Reads: New CEO of PacBio, Mark Van Oene

Mark Van Oene has just taken over as CEO of Pacific Biosciences, and Mendelspod is his first interview in the new job. He began his career as a scientist studying cystic fibrosis genetics at Toronto’s SickKids, then spent fifteen years at Illumina, rising from its first sales rep in Canada to Chief Commercial Officer. He joined PacBio in 2021 as COO and has spent the past five years helping build the product portfolio he now inherits as CEO. He joins us today with a clear message: PacBio is choosing long reads. The company has moved on from it...

August 27, 2026

Serge Saxonov on What’s Next for 10x Genomics

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com 10x Genomics has been remarkably good at figuring out where biology is going next. In this wide-ranging conversation, co-founder and CEO Serge Saxonov explains why. Despite decades of genomics, “we still understand very little biology.” For 10x, the way forward has been to build better tools for measuring it and to work backward from the biological questions rather than forward from a particular technology. That philosophy helped drive the single-cell revolution and 10x’s move into spatial biolog...

Similar podcasts